22 February 2024 - Australia risks “being pushed to the back of the queue” of countries to gain access to a revolutionary cancer treatment that can put those facing imminent death into remission amid a standoff between medical technology advisers and a pharmaceutical company.

The MSAC has deferred a decision to approve public funding for a type of CAR-T cell therapy – dubbed “the future of cancer treatment – for the rare blood cancer multiple myeloma, leaving hundreds of terminally ill patients in limbo.

Read The Australian article